Although the benefits of thrombolytic therapy are well established in patients younger than age 75 years with acute ST-elevation myocardial infarction, the value of thrombolytic treatment in ...

However, the literature has shown that survival is not well linked to preserving left ventricular function, [3] and in randomized trials, thrombolysis long after irreversible myocardial necrosis ...

Pinto and co-workers conducted retrospective analyses of data from the Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In Myocardial Infarction 28 (CLARITY–TIMI 28) study to examine ...

Fibrinolytic therapy, also known as thrombolytic therapy ... therapy is used in the treatment of a ST segment elevation myocardial infarction (STEMI), acute stroke and other less common ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at exploring immune-related genes and their expression changes in myocardial ...

Myocardial infarction remains one of the leading causes of mortality, which is usually complicated by the occurrence of ischemic ventricular arrhythmias, which in turn increase the risk of sudden ...